Seamless solutions from target to IND

What Biocytogen Offers

IND Enabling
Clinical Trial
Therapeutics
400K+ Fully Human Antibody Library
  • 20+ Dual-TAA Targeting BsADCs
  • 200+ TAA Projects for Plug & Play
  • 30+ Autoimmune Projects
  • 10+ TCR-Mimic Projects
  • 200+ VHH Antibody Project
  • 70+ mAb/bsAbs Projects Targeting GPCRs
3,300+ Off-the-Shelf Animal & Cell Models
  • Drug-Targeted Humanized Models
  • Disease Models (Oncology, Autoimmune, Metabolism, Neuroscience, etc.)
  • Immunodeficient Models
Biocytogen's Proprietary Gene-Editing Powered

Preclinical Animal Models and Services

Leveraging proprietary, high-efficiency gene-editing technologies, Biocytogen is a global leader in animal and cell model generation for preclinical research. Through BioMice™, we offer thousands of off-the-shelf drug-targeted humanized models, providing ready-to-use solutions for drug efficacy, safety, and mechanistic studies.

Beyond model generation, Biocytogen accelerates global drug discovery with comprehensive preclinical pharmacology and gene-editing services, driving breakthroughs in oncology, immunology, and beyond.

Gene Editing
Animal Models
Pharmacology Services
Biocytogen's SUPCE™-Based

Fully Human Antibody Discovery Platforms

Leveraging its cutting-edge gene-editing expertise, Biocytogen has developed the proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE™) technology. Based on this innovative technique, Biocytogen employs a large-fragment in situ replacement strategy to seamlessly substitute human antibody gene sequences while preserving the mouse Fc region. This ensures the production of fully human antibodies while supporting normal immune system development, laying the foundation of Biocytogen's RenMice® antibody discovery platforms.

The RenMice® family—featuring RenMab™, RenLite®, RenNano®, RenTCRmimic™, and RenMice® KO—offers unparalleled versatility in antibody discovery:

RenMab™
mAb Platform
  • Target KO strategy
  • Great diversity & affinity
  • Novel binding epitopes
  • Multi-species cross-reactivity
RenLite®
BsAb Platform
  • Common light chain
  • Convenient assembly
  • High purity and good developabilities
RenLite®
BsADC Platform
  • 200+ TAA targets
  • Good developabilities
  • Increased potency & reduced toxicity
RenNano®
Hu-VHH Platform
  • Good permeability
  • Small and good building blocks for bi-/multi-specific Ab, CAR-1 etc.
RenTCR-mimic™
TCR-mimic Platform
  • Intracellular TAAs
  • High specificity to the target HLA complex
RenMice® KO
GPCR Platform
  • Targeting challenging GPCRs
  • Targeting complex transmembrane structure

News & Events

Stay updated with our latest news, events, and insights.

View More on Insights

Contact Us for Service

Connect with Biocytogen to advance your drug discoveries together

Joy Wang, Ph.D.

Principal Scientist, Genomic Medicine Preclinical Pharmacology
Alexion Pharmaceuticals

I wanted to express our sincere gratitude for your invaluable collaboration. Your support and dedication have significantly contributed to our project timeline. We truly appreciate your professionalism and look forward to more opportunities to collaborate in the near future. Thank you once again for your exceptional support.

Edward Rocheta

Vice President, Business Operations
Be Biopharma

Since 2021, we have developed five different B-NDG hIL6 models with Biocytogen to support Be Bio's development pipeline (Fabre, MPS-IV, Niemann Pick A/B, Hemophilia B, and Hypophosphatasia). We view Biocytogen's capabilities as complementary to Be Bio's, and a strong partnership will enable us to leverage your strengths to advance our current and future drug development programs.

Zhongcong Xie, M.D., Ph.D., FASA

Director, Geriatric Anesthesia Research Unit
Director, Basic Science Research Department of Anesthesia, Critical Care and Pain Medicine, MGH

Biocytogen's gene targeting services have always been professional, efficient and productive. The services have helped us to achieve our goal.

Collaborate with Us
Partner with Us

Biocytogen partners with global companies to accelerate drug discovery and development. Our integrated platforms—including fully human antibody discovery, target-humanized models, preclinical pharmacology, and custom gene-editing—streamline the translation of promising biological insights into breakthrough therapies.

our featured partners